|
1
|
Horwich A, Parker C and de Reijke T:
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis,
treatment and follow-up. Ann Oncol. 24(Suppl 6): vi106–vi114. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mohler JL, Kantoff PW, Armstrong AJ,
Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington
TA, Higano CS, et al National Comprehensive Cancer Network:
Prostate cancer, version 2.2014. J Natl Compr Canc Netw.
12:686–718. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zietman AL, Bae K, Slater JD, Shipley WU,
Efstathiou JA, Coen JJ, Bush DA, Lunt M, Spiegel DY, Skowronski R,
et al: Randomized trial comparing conventional-dose with high-dose
conformal radiation therapy in early-stage adenocarcinoma of the
prostate: Long-term results from proton radiation oncology
group/american college of radiology 95-09. J Clin Oncol.
28:1106–1111. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Baumann M, Krause M and Hill R: Exploring
the role of cancer stem cells in radioresistance. Nat Rev Cancer.
8:545–554. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Johansson S, Aström L, Sandin F, Isacsson
U, Montelius A and Turesson I: Hypofractionated proton boost
combined with external beam radiotherapy for treatment of localized
prostate cancer. Prostate Cancer. 2012:6548612012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Khuntia D, Reddy CA, Mahadevan A, Klein EA
and Kupelian PA: Recurrence-free survival rates after external-beam
radiotherapy for patients with clinical T1-T3 prostate carcinoma in
the prostate-specific antigen era: What should we expect? Cancer.
100:1283–1292. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cooper BT and Sanfilippo NJ: Concurrent
chemoradiation for high-risk prostate cancer. World J Clin Oncol.
6:35–42. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
West CM, Davidson SE, Elyan SA, Swindell
R, Roberts SA, Orton CJ, Coyle CA, Valentine H, Wilks DP, Hunter
RD, et al: The intrinsic radiosensitivity of normal and tumour
cells. Int J Radiat Biol. 73:409–413. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Balmukhanov SB, Yefimov ML and Kleinbock
TS: Acquired radioresistance of tumour cells. Nature. 216:709–711.
1967. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wei K, Kodym R and Jin C: Radioresistant
cell strain of human fibrosarcoma cells obtained after long-term
exposure to x-rays. Radiat Environ Biophys. 37:133–137. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
McDermott N, Meunier A, Mooney B, Nortey
G, Hernandez C, Hurley S, Lynam-Lennon N, Barsoom SH, Bowman KJ,
Marples B, et al: Fractionated radiation exposure amplifies the
radioresistant nature of prostate cancer cells. Sci Rep.
6:347962016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Brown JM and Giaccia AJ: The unique
physiology of solid tumors: Opportunities (and problems) for cancer
therapy. Cancer Res. 58:1408–1416. 1998.PubMed/NCBI
|
|
14
|
Brown JM and Wilson WR: Exploiting tumour
hypoxia in cancer treatment. Nat Rev Cancer. 4:437–447. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Harada H, Kizaka-Kondoh S, Li G, Itasaka
S, Shibuya K, Inoue M and Hiraoka M: Significance of HIF-1-active
cells in angiogenesis and radioresistance. Oncogene. 26:7508–7516.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Harada H: Hypoxia-inducible factor
1-mediated characteristic features of cancer cells for tumor
radioresistance. J Radiat Res (Tokyo). 57(Suppl 1): i99–i105. 2016.
View Article : Google Scholar
|
|
17
|
Chang HW, Nam HY, Kim HJ, Moon SY, Kim MR,
Lee M, Kim GC, Kim SW and Kim SY: Effect of β-catenin silencing in
overcoming radioresistance of head and neck cancer cells by
antagonizing the effects of AMPK on Ku70/Ku80. Head Neck. 38(Suppl
1): E1909–E1917. 2016. View Article : Google Scholar
|
|
18
|
Cojoc M, Peitzsch C, Kurth I, Trautmann F,
Kunz-Schughart LA, Telegeev GD, Stakhovsky EA, Walker JR, Simin K,
Lyle S, et al: Aldehyde dehydrogenase is regulated by β-catenin/TCF
and promotes radioresistance in prostate cancer progenitor cells.
Cancer Res. 75:1482–1494. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhao JH, Luo Y, Jiang YG, He DL and Wu CT:
Knockdown of β-catenin through shRNA cause a reversal of EMT and
metastatic phenotypes induced by HIF-1α. Cancer Invest. 29:377–382.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Luo Y, Lan L, Jiang YG, Zhao JH, Li MC,
Wei NB and Lin YH: Epithelial-mesenchymal transition and migration
of prostate cancer stem cells is driven by cancer-associated
fibroblasts in an HIF-1α/β-catenin-dependent pathway. Mol Cells.
36:138–144. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang J, Zhou D, He X, Wang Y, Hu W, Jiang
L and Dou J: Effect of downregulated β-catenin on cell
proliferative activity, the sensitivity to chemotherapy drug and
tumorigenicity of ovarian cancer cells. Cell Mol Biol
(Noisy-le-grand). 57(Suppl): OL1606–OL1613. 2011.
|
|
22
|
Rahbar Saadat Y, Saeidi N, Zununi Vahed S,
Barzegari A and Barar J: An update to DNA ladder assay for
apoptosis detection. Bioimpacts. 5:25–28. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gouazé-Andersson V, Delmas C, Taurand M,
Martinez-Gala J, Evrard S, Mazoyer S, Toulas C and
Cohen-Jonathan-Moyal E: FGFR1 induces glioblastoma radioresistance
through the PLCγ/Hif1α pathway. Cancer Res. 76:3036–3044. 2016.
View Article : Google Scholar
|
|
24
|
Marampon F, Gravina GL, Zani BM, Popov VM,
Fratticci A, Cerasani M, Di Genova D, Mancini M, Ciccarelli C,
Ficorella C, et al: Hypoxia sustains glioblastoma radioresistance
through ERKs/DNA-PKcs/HIF-1α functional interplay. Int J Oncol.
44:2121–2131. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Orsulic S, Huber O, Aberle H, Arnold S and
Kemler R: E-cadherin binding prevents beta-catenin nuclear
localization and beta-catenin/LEF-1-mediated transactivation. J
Cell Sci. 112:1237–1245. 1999.PubMed/NCBI
|
|
26
|
Zhang Y, Fan N and Yang J: Expression and
clinical significance of hypoxia-inducible factor 1α, Snail and
E-cadherin in human ovarian cancer cell lines. Mol Med Rep.
12:3393–3399. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang L, Zhang XM, Li Z, Liu XJ, Chai J,
Zhang GY and Cheng YF: Overexpression of nuclear β-catenin in
rectal adenocarcinoma is associated with radioresistance. World J
Gastroenterol. 19:6876–6882. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang Q, Gao M, Luo G, Han X, Bao W, Cheng
Y, Tian W, Yan M, Yang G and An J: Enhancement of radiation
sensitivity in lung cancer cells by a novel small molecule
inhibitor that targets the β-catenin/Tcf4 interaction. PLoS One.
11:e01524072016. View Article : Google Scholar
|
|
29
|
Nelson WJ and Nusse R: Convergence of Wnt,
beta-catenin, and cadherin pathways. Science. 303:1483–1487. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Guarino M: Epithelial-mesenchymal
transition and tumour invasion. Int J Biochem Cell Biol.
39:2153–2160. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bütof R, Dubrovska A and Baumann M:
Clinical perspectives of cancer stem cell research in radiation
oncology. Radiother Oncol. 108:388–396. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Peitzsch C, Kurth I, Kunz-Schughart L,
Baumann M and Dubrovska A: Discovery of the cancer stem cell
related determinants of radioresistance. Radiother Oncol.
108:378–387. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xi Y, Wei Y, Sennino B, Ulsamer A, Kwan I,
Brumwell AN, Tan K, Aghi MK, McDonald DM, Jablons DM, et al:
Identification of pY654-β-catenin as a critical co-factor in
hypoxia-inducible factor-1α signaling and tumor responses to
hypoxia. Oncogene. 32:5048–5057. 2013. View Article : Google Scholar
|
|
34
|
Roura S, Miravet S, Piedra J, García de
Herreros A and Duñach M: Regulation of E-cadherin/Catenin
association by tyrosine phosphorylation. J Biol Chem.
274:36734–36740. 1999. View Article : Google Scholar : PubMed/NCBI
|
